Back
 JCDSA  Vol.2 No.4 , December 2012
Direct Melanocytes Transplant from Normal Donor Area into Vitiliginous Recipient Area by Dermabrasion Technique
Abstract: Background: Vitiligo is an autoimmune pigmentory disorder, that affects all age group that is treated by many medical treatments but some of them might need surgical therapy. Objective: To evaluate the dermabrasion technique in the treatment of vitiligo by direct transfer of melanocytes from the dermabraded normal donor area to the vitiliginous recipient area. Patients and Methods: This is a case interventional study was done in Department of Dermatology/Baghdad Teaching Hospital from February 2011-March 2012. Nine Patients with vitiligo were enrolled in this study with different clinical types of vitiligo including 5 segmental, 2 generalized and 2 localized. The donor and recipient areas were anesthetized at the same time with xylocain alone. Dermabrasion of recipient area was done first by manual abrader and left for few minutes until the oozing was stopped. Then the donor area was similarly dermabraded and the dermabraded tissue including the epidermis and superficial epidermis was immediately transferred into the recipient area and dressing was applied. Removal of the dressing was done after 10 - 14 days from the operative time. Follow up was done every 2 weeks in the first month then monthly for six months to record the result of implantation and repigmentation. Results: The re-pigmentation started one month after the operation as small macules and this increased gradually over time: the mean rate of re-pigmentation was 13% at 2 months, 27.8% at 4 months and 36.78% at 6 months. In addition, sun light exposure was applied to enhance re-pigmentation. The pigmentation was diffuse and not follicular in shape. Conclusion: Direct transfer of melanocytes from normal donor area into vitiliginous recipient area by dermabrasion technique was easy, rapid and non-costly and gave 36.78% mean rate of pigmentation at 6 months follow up and without complications.
Cite this paper: K. Sharquie, A. Noaimi and H. Al-Mudaris, "Direct Melanocytes Transplant from Normal Donor Area into Vitiliginous Recipient Area by Dermabrasion Technique," Journal of Cosmetics, Dermatological Sciences and Applications, Vol. 2 No. 4, 2012, pp. 288-293. doi: 10.4236/jcdsa.2012.24055.
References

[1]   K. E. Sharquie, “Vitiligo,” Clinical and Experimental Dermatol, Vol. 9, No. 2, 1984, pp. 117-126.

[2]   K. E. Sharquie, “The Histology and Immunopathology of Vitiligo,” Ph.D. Thesis, University of Sheffield, England, 1982.

[3]   K. E. Sharquie, “Stages of Depigmentation in Vitiligo,” Iraqi Medical Journal, Vol. 36, 1988, pp. 47-50.

[4]   K. E. Sharquie, S. H. Mehenna, A. A Naji and H. Al-Azzawi, “Inflammatory Changes in Vitiligo: Stage I and II Depigmentation,” American Journal of Dermatopathology, Vol. 26, No. 2, 2004, p. 108.

[5]   M. B. Abdel-Naser, S. K. Hann and J. C. Bystryn, “Oral Psoralen with UV-A Therapy Releases Circulating Growth Factors That Stimulates Cell Proliferation,” Archives of Dermatology, Vol. 133, No. 12, 1997, pp. 1530-1533.

[6]   K. E. Shaquie and M. H. Majeed, “Treatment of Vitiligo by Topical Application of 5% Tincture Iodine in Comparison with 8-Methoxypsoralen Lotion (0.3%),” Journal of Pan-Arab League of Dermatologist, Vol. 12, No. 1, 2001, pp. 27-33.

[7]   M. D. Njoo, J. D. Bos and W. Westerhof, “Treatment of Generalized Vitiligo in Children with Narrow-Band (TL-01) UVB Radiation Therapy,” Journal of the American Academy of Dermatology, Vol. 42, No. 2, 2011, pp. 245-253. doi:10.1016/S0190-9622(00)90133-6

[8]   K. E. Sharquie, H. R. Al-Hammay and M. H. Al-Obeidy, “Treatment of Vitiligo with Topical Tincture Iodine 5% Solution and Ultaraviolet Light,” Thesis for Fellowship of Iraqi Board for Medical Specializations in Dermatology and Venereology, 2005.

[9]   K. E. Sharquie and M. Y. Saeed, “Treatment of Vitiligo with Topical 15% Lactic Acid Solution in Comparison with Other Topical Therapies in Vitiligo,” Thesis for Fellowship of Iraqi Board for Medical Specializations in Dermatology and Venereology, 2002, pp. 36-46.

[10]   K. E. Sharquie and M. S. Abdulla, “Treatment of Vitiligo by Topical Application of Lactic Acid 15% in Combination with Ultra Violet-A,” Saudi Medical Journal, Vol. 25, No. 5, 2005, pp. 1013-1015.

[11]   S. S. Savant, “Miniature Punch Grafting,” In: S. S. Savant, Ed., Association of Scientific Cosmetology and Dermatosurgeons Textbook of Dermatosurgery and Cosmetology, 2nd Edition, ASCAD, Mumbai, 2005, pp. 359-369.

[12]   S. Malakar and S. Dhar, “Repigmentation of Vitiligo Patches by Transplantation of Hair Follicles,” International Journal of Dermatology, Vol. 38, No. , 1999, pp. 237-238.

[13]   R. Falabella, “Surgical Therapies for Vitiligo and Other Leukoderma, Part 1: Minigrafting and Suction Epidermal Grafting,” Dermatol Ther, Vol. 14, No. , 2001, pp. 7-14.

[14]   K. E. Sharquie, “Pigment Minigrafting as Treatment for Dermatomal Vitiligo,” The 9th Scientific Congress, College of Medicine, University of Baghdad, Baghdad, 1996.

[15]   M. Ozdemir, O. Cetinkale, R. Wolf, A. Kotogyan, C. Mat, B. Tuzun and Y. Tuzun, “Comparison of Two Surgical Approaches for Treating Vitiligo: A Preliminary Study,” International Journal of Dermatology, Vol. 41, No. 3, 2002, pp. 135-138.

[16]   A. M. Kahn and M. J. Cohen, “Treatment by Dermabrasion and Epithelial Sheet Grafting,” Journal of the American Academy Dermatology, Vol. 33, No. 4, 1995, pp. 646-648.

[17]   K. Agrawal and A. Agrawal, “Repigmentation with Dermabrasion and Thin Split-Thickness Skin Graft,” Dermatologic Surgery, Vol. 21, No. 4, 1995, pp. 295-300.

[18]   S. V. Mulekar, “Long-Term Follow-Up Study of 142 Patients with Vitiligo Vulgaris Treated by Autologous, Non-Cultured Melanocyte-Keratinocyte Cell Transplantation,” International Journal of Dermatology, Vol. 44, No. 10, 2005, pp. 841-845.

[19]   S. V. Mulekar, A. Al Issa and A. Al Eisa, “Treatment of Vitiligo on Difficult-to-Treat Sites Using Autologous Non-Cultured Cellular Grafting,” Dermatologic Surgery, Vol. 35, No. 1, 2009, pp. 66-71.

[20]   S. V. Mulekar, “Stable Vitiligo Treated by a Combination of Low-Dose Oral Pulse Betamethasone and Autologous, Melanocyte-Keratinocyte Cell Transplantation,” Dermatologic Surgery, Vol. 32, No. 4, 2006, pp. 536-541. doi:10.1111/j.1524-4725.2006.32109.x

[21]   S. V. Mulekar, B. Ghwish, A. Al Issa and A. Al Eisa, “Treatment of Vitiligo Leasions by ReCell vs. Conventional Melanocyte-Keratinocyte Transplantation: Pilot Study,” The British Journal of Dermatology, Vol. 158, No. 1, 2007, pp. 45-49.

[22]   B. M. El-Zawahry, N. S. Zaki, D. A. Bassiouny, R. M. Sobhi, A. Zaghloul, M. M. Khorshied and H. M. Gouda, “Atologous Melanocyte-Keratinocyte Suspension in the Treatment of Vitiligo,” Journal of European Academy of Dermatology and Venereology, Vol. 25, No. 2, 2011, pp. 215-220.

[23]   R. Czajkowski, W. Placer, T. Drewa, B. Kowaliszyn, J. Sir and W. Weiss, “Autologous Cultured Melanocytea in Vitiligo Treatment,” Dermatologic Surgery, Vol. 33, No. 9, 2007, pp. 1027-1036.

[24]   S. Sethi, B. B. Mahajan, R. R. Gupta and A. Ohri, “Comparative Evaluation of the Therapeutic Efficacy of Dermabrasion, Dermabrasion Combined with Topical 5% 5-Fluorouracil Cream, and Dermabrasion Combined with Topical Placentrex Gel in Localized Stable Vitiligo,” International Journal of Dermatology, Vol. 46, No. 8, 2007, pp. 875-879.

[25]   N. S. Mohamed, M. F. Elgoweini and N. A. Khad, “Dermatomal Vitiligo: Therapeutic Implication of Dermabration,” Journal of Pan-Arab Leaguo of Dermatologists, Vol. 19, 2008, pp. 21-29.

[26]   P. Redondo, A. G. Azcarate, L. Marques, M. G. Guzman, E. Andreu and F. Prosper, “Amniotic Membrane as a Scaffold for Melanocytes Transplantation in Patients with Stable Vitiligo,” Dermatology Research and Practice, 2011, 6 p. Article ID 532139. doi:10.1155/2011/532139

[27]   O. T. Vázquez-Martínez, H. G. Matínez-Rodríguez, L. Velásquez-Arenas, D. Banos-González, R. Ortíz-López, G. Padilla-Rivas, O. Welsh and J. Ocampo-Candiani, “Treatment of Vitiligo with a Melanocytes-Keratiocyte Cell Suspension versus Dermabrasion Only: A Pilot Study with a 12 Month Follow up,” Journal of Drug in Dermatology, Vol. 10, No. 9, 2011, pp. 1032-1036.

 
 
Top